For example, deletion of CTCF in the domain may result in an interaction between the enhancer and a glioma oncogene (Katainen et al., 2015); the binding site of CTCF is the main mutation hot spot of the non-coding cancer genome (Ohlsson et al., 2001); zinc finger mutation or abnormal target selective methylation destroy the spectrum of target specificity and is related to cancer (Phillips and Corces, 2009). This evidence concerns the gene CTCF and glioma.